ArticleHereditas2025
PDE3B and HBB are key prognostic biomarkers driving cell proliferation and regulating immune microenvironment in breast cancer.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is a heterogeneous malignancy with diverse tumor subpopulations and complex tumor-immune interactions. This study explores the prognostic and functional roles of PDE3B and HBB in breast cancer, focusing on their contributions to proliferation and immune microenvironment modulation.
methodsSingle-cell RNA sequencing (scRNA-seq) and TCGA data were analyzed to identify malignant subpopulations and prognostic genes. Differential gene expression, KEGG enrichment, LASSO regression, and Kaplan-Meier survival analyses were performed. Immune infiltration was assessed using EPIC deconvolution. Functional validation included qRT-PCR, IHC, Western blot, and proliferation assays in MDA-MB-231 cells.
resultsMalignant cell type 3 exhibited the highest proliferative potential. PDE3B and HBB were identified as prognostic markers, strongly associated with poor survival and immune cell infiltration. Overexpression of these genes enhanced proliferation, while their knockout suppressed it.
conclusionPDE3B and HBB drive breast cancer proliferation and immune modulation, making them promising biomarkers and therapeutic targets. Further research should assess their potential in targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.